Literature DB >> 15528701

Outbreak of carbapenem-resistant Pseudomonas aeruginosa producing VIM-8, a novel metallo-beta-lactamase, in a tertiary care center in Cali, Colombia.

M P Crespo1, N Woodford, A Sinclair, M E Kaufmann, J Turton, J Glover, J D Velez, C R Castañeda, M Recalde, D M Livermore.   

Abstract

The prevalence of imipenem resistance among Pseudomonas aeruginosa isolates at a 195-bed tertiary care medical center in Cali, Colombia, rose from 2% in 1996 to 28% in 1997 and to over 40% in 2003. Many isolates showed high-level multiresistance, and phenotypic characterization suggested the spread of a predominant strain with minor variants. Sixty-six resistant isolates collected between February 1999 and July 2003 from hospitalized patients (n = 54) and environmental samples (n = 12) were subjected to a fuller analysis. Genetic fingerprints were compared by pulsed-field gel electrophoresis (PFGE) of SpeI-digested genomic DNA, and bla(IMP) and bla(VIM) genes were sought by PCR. PFGE and serotyping indicated that 52 of the 66 isolates belonged to a single strain, with 82% similarity; the PFGE pattern for this organism was designated pattern A. Two further pairs of isolates represented single strains; the remaining nine isolates were unique, and in the case of one isolate, no satisfactory PFGE profile could be obtained. The pattern A isolates were mostly of serotype O12 and were highly resistant to imipenem (MICs, 32 to >256 microg/ml), with this resistance decreased eightfold or more in the presence of EDTA. They yielded amplicons with bla(VIM)-specific primers, and sequencing of DNA from a representative isolate revealed bla(VIM-8), a novel allele with three polymorphisms compared with the sequence of bla(VIM-2). Two of these nucleotide changes were silent, but the third determined a Thr139Ala substitution. Only 4 of 13 resistant isolates (2 clinical isolates and 2 environmental isolates) assigned to other PFGE types carried bla(VIM) alleles, whereas the others were less multiresistant and mostly had lower levels of imipenem resistance (MICs, < or =32 microg/ml) which was not significantly reduced by EDTA. No bla(IMP) alleles were detected. During 2003, when the environmental study was undertaken, serotype O12 isolates with bla(VIM) were recovered from sinks and stethoscopes in the most-affected units, although not from the hands of staff; the problem declined once these reservoirs were disinfected and hygienic precautions were reinforced.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15528701      PMCID: PMC525211          DOI: 10.1128/JCM.42.11.5094-5101.2004

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  35 in total

1.  Carbapenem-hydrolysing VIM-2 metallo- beta-lactamase in Pseudomonas aeruginosa from Greece.

Authors:  A Mavroidi; A Tsakris; E Tzelepi; S Pournaras; V Loukova; L S Tzouvelekis
Journal:  J Antimicrob Chemother       Date:  2000-12       Impact factor: 5.790

Review 2.  Prescribing guidelines for severe Pseudomonas infections.

Authors:  Helen Giamarellou
Journal:  J Antimicrob Chemother       Date:  2002-02       Impact factor: 5.790

3.  IMP-1 carbapenemase detected in an Acinetobacter clinical isolate from the UK.

Authors:  Luke Tysall; Mark W Stockdale; Paul R Chadwick; Marie-France I Palepou; Kevin J Towner; David M Livermore; Neil Woodford
Journal:  J Antimicrob Chemother       Date:  2002-01       Impact factor: 5.790

4.  Determination of minimum inhibitory concentrations.

Authors:  J M Andrews
Journal:  J Antimicrob Chemother       Date:  2001-07       Impact factor: 5.790

5.  Characterization of Pseudomonas aeruginosa isolates: occurrence rates, antimicrobial susceptibility patterns, and molecular typing in the global SENTRY Antimicrobial Surveillance Program, 1997-1999.

Authors:  A C Gales; R N Jones; J Turnidge; R Rennie; R Ramphal
Journal:  Clin Infect Dis       Date:  2001-05-15       Impact factor: 9.079

6.  Antimicrobial susceptibilities among clinical isolates of extended-spectrum cephalosporin-resistant Gram-negative bacteria in a Taiwanese University Hospital.

Authors:  Shio-Shin Jean; Lee-Jene Teng; Po-Ren Hsueh; Shen-Wu Ho; Kwen-Tay Luh
Journal:  J Antimicrob Chemother       Date:  2002-01       Impact factor: 5.790

7.  Nosocomial outbreak of carbapenem-resistant Pseudomonas aeruginosa with a new bla(IMP) allele, bla(IMP-7).

Authors:  Alan Patrick Gibb; Chanwit Tribuddharat; Richard A Moore; Thomas J Louie; Wally Krulicki; David M Livermore; Marie-France I Palepou; Neil Woodford
Journal:  Antimicrob Agents Chemother       Date:  2002-01       Impact factor: 5.191

8.  Metallo-beta-lactamases in clinical Pseudomonas isolates in Taiwan and identification of VIM-3, a novel variant of the VIM-2 enzyme.

Authors:  J J Yan; P R Hsueh; W C Ko; K T Luh; S H Tsai; H M Wu; J J Wu
Journal:  Antimicrob Agents Chemother       Date:  2001-08       Impact factor: 5.191

9.  Hospital outbreak of carbapenem-resistant Pseudomonas aeruginosa producing VIM-1, a novel transferable metallo-beta-lactamase.

Authors:  G Cornaglia; A Mazzariol; L Lauretti; G M Rossolini; R Fontana
Journal:  Clin Infect Dis       Date:  2000-11-06       Impact factor: 9.079

10.  bla(VIM-2) cassette-containing novel integrons in metallo-beta-lactamase-producing Pseudomonas aeruginosa and Pseudomonas putida isolates disseminated in a Korean hospital.

Authors:  Kyungwon Lee; Jong Back Lim; Jong Hwa Yum; Dongeun Yong; Yunsop Chong; June Myung Kim; David M Livermore
Journal:  Antimicrob Agents Chemother       Date:  2002-04       Impact factor: 5.191

View more
  39 in total

1.  First nosocomial outbreak of Pseudomonas aeruginosa producing an integron-borne metallo-beta-lactamase (VIM-2) in the United States.

Authors:  K Lolans; A M Queenan; K Bush; A Sahud; J P Quinn
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

2.  First identification of Pseudomonas aeruginosa isolates producing a KPC-type carbapenem-hydrolyzing beta-lactamase.

Authors:  Maria Virginia Villegas; Karen Lolans; Adriana Correa; Juan Nicolas Kattan; Jaime A Lopez; John P Quinn
Journal:  Antimicrob Agents Chemother       Date:  2007-01-29       Impact factor: 5.191

3.  First detection of metallo-beta-lactamase VIM-2 in Pseudomonas aeruginosa isolates from Colombia.

Authors:  Maria Virginia Villegas; Karen Lolans; Maria del Rosario Olivera; Carlos José Suarez; Adriana Correa; Anne Marie Queenan; John P Quinn
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

4.  Bloodstream infections with metallo-beta-lactamase-producing Pseudomonas aeruginosa: epidemiology, microbiology, and clinical outcomes.

Authors:  Alexandre R Marra; Carlos Alberto P Pereira; Ana Cristina Gales; Liana C Menezes; Ruy Guilherme R Cal; José Marconi A de Souza; Michael B Edmond; Cynthia Faro; Sérgio B Wey
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

Review 5.  Carbapenemases: the versatile beta-lactamases.

Authors:  Anne Marie Queenan; Karen Bush
Journal:  Clin Microbiol Rev       Date:  2007-07       Impact factor: 26.132

6.  Environmental Reservoirs of Nosocomial Infection: Imputation Methods for Linking Clinical and Environmental Microbiological Data to Understand Infection Transmission.

Authors:  Lensing Julia; K Vilankar; Hyojung Kang; Donald E Brown; Amy Mathers; Laura E Barnes
Journal:  AMIA Annu Symp Proc       Date:  2018-04-16

7.  Novel VIM metallo-beta-lactamase variant, VIM-24, from a Klebsiella pneumoniae isolate from Colombia.

Authors:  Maria Camila Montealegre; Adriana Correa; David F Briceño; Natalia C Rosas; Elsa De La Cadena; Sory J Ruiz; Maria F Mojica; Ruben Dario Camargo; Ivan Zuluaga; Adriana Marin; John P Quinn; Maria Virginia Villegas
Journal:  Antimicrob Agents Chemother       Date:  2011-01-31       Impact factor: 5.191

8.  Rapid Identification of Five Classes of Carbapenem Resistance Genes Directly from Rectal Swabs by Use of the Xpert Carba-R Assay.

Authors:  Nicholas M Moore; Rafael Cantón; Edoardo Carretto; Lance R Peterson; Robert L Sautter; Maria M Traczewski
Journal:  J Clin Microbiol       Date:  2017-05-17       Impact factor: 5.948

Review 9.  A systematic review and meta-analyses show that carbapenem use and medical devices are the leading risk factors for carbapenem-resistant Pseudomonas aeruginosa.

Authors:  Anne F Voor In 't Holt; Juliëtte A Severin; Emmanuel M E H Lesaffre; Margreet C Vos
Journal:  Antimicrob Agents Chemother       Date:  2014-02-18       Impact factor: 5.191

10.  Four Year Trend of Carbapenem-Resistance in Newly Opened ICUs of a University-Affiliated Hospital of South Korea.

Authors:  Bo Min Kim; Eun Ju Jeon; Ju Young Jang; Jin-Won Chung; Jihoon Park; Jae Chol Choi; Jong Wook Shin; In Won Park; Byoung Whui Choi; Jae Yeol Kim
Journal:  Tuberc Respir Dis (Seoul)       Date:  2012-04-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.